3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Unknown
6
Recruiting
4
Completed
2
Withdrawn
1
Not yet recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Stomach Neoplasms
1
Pancreatic Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms, Unknown Primary
1
Gastrointestinal Stromal Tumors
1
Gastrointestinal Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Colorectal Neoplasms
1
Biliary Tract Neoplasms
1
Interventions
pembrolizumab
224
Cyclophosphamide
192
Radiotherapy
183
Nivolumab
180
Carboplatin
153
Cisplatin
114
Paclitaxel
112
Dexamethasone
110
Radiosurgery
104
Magnetic Resonance Spectroscopy
97
Surveys and Questionnaires
91
Ipilimumab
81
Doxorubicin
79
Lenalidomide
76
durvalumab
75
Rituximab
75
atezolizumab
72
Radiation
72
venetoclax
69
fludarabine
68
Standard of Care
68
Gemcitabine
68
Specimen Handling
65
Etoposide
64
Capecitabine
64
Bevacizumab
62
Oxaliplatin
59
Docetaxel
58
Biopsy
58
Radiotherapy, Intensity-Modulated
56
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
OTHER
×
Poly(ADP-ribose) Polymerase Inhibitors
×
Clear all
NCT04584008
2024-10-15
VISIONARY
Peking University
Phase NA
Active not recruiting
600 enrolled